TriAgenics, the pioneer of fully guided tooth bud ablation, has announced the grant of four additional European patents, further establishing the company’s global IP position for a novel technology designed to prevent third molar formation. Germany, France, Italy, and the United Kingdom are the latest European countries to grant a patent for TriAgenics’ ablation probe system.
TriAgenics’ patented micro-ablation technology is the cornerstone behind Zero3 TBA, a preventive-care treatment for children ages 6–12. The treatment prevents the formation of third molars through the application of low-level, CT-guided microwave energy. This new dental modality is based on microwave ablation techniques commonly used in the medical field. TriAgenics plans to introduce Zero3 TBA to the U.S. dental market in 2025, following clearance from the U.S. Food and Drug Administration.
Following FDA clearance, dentists will send patient CBCT and intraoral scans to TriAgenics, which will fabricate custom Zero3 kits and ship them to dentists to perform the one-minute treatment using TriAgenics’ proprietary ablation technology.
TriAgenics believes the economic impact of Zero3 TBA treatment will be massive. Total expenditures associated with extracting third molars and correcting related problems are estimated to be nearly $5 billion in the U.S. alone.
TriAgenics estimates its total addressable market will be greater than $2.5 billion annually when Zero3 TBA treatment becomes the new standard of care in the U.S.
About TriAgenics
TriAgenics is a disruptive oral healthcare company that has pioneered the development of a one-minute treatment designed to prevent third molars from ever forming. Based on extensive animal trials, TriAgenics’ Zero3 TBA system is expected to eliminate all pain and complications normally associated with third molar extraction. TriAgenics’ mission is to provide dentists and their patients with a non-surgical alternative that has no painful recovery or need to miss work or school.
Source: www.triagenics.com
News 09 October 2025
TriAgenics, Inc., a privately held company pioneering a non-surgical approach to third molar (wisdom tooth) prevention, today announced that it expanded its Series B-1 funding round in response to...
News 05 May 2025
TriAgenics, Inc., pioneer of Zero3 TBA, a fully guided tooth bud ablation system designed to prevent third molar formation, announced that David Thrower has been named president and CEO.
News 22 September 2026
New FlexPayments features help Open Dental practices convert more diagnosed treatment into scheduled care and automatically recover credit card processing fees they’ve been absorbi
News 05 August 2026
Specialty1 Partners (S1P), the nation’s leading doctor-founded and doctor-led specialty dental partnership organization, recently announced its newest joint venture partnership wit
News 04 August 2026
Rob Brian brings more than 15 years of dental industry experience to Menlo Dental Transitions, where he will advise dentists throughout Utah and the surrounding region.
Continuous innovation across the DEXIS ecosystem helps clinicians work with greater clarity, confidence, and efficiency
News 07 October 2026
Lightspun and SDB Partner to Speed Dental Provider Onboarding
Lightspun’s AI automation cuts provider onboarding from up to 12 weeks to under two weeks across SDB’s 300-provider, 25-state network
News 07 October 2026
Smile Train invites New York City to share moments of joy and raise awareness for people affected by cleft at Grand Central Terminal.
Editorials 07 October 2026
Woman’s skull likely proof of ancient nose amputation, says College of Dentistry professor
Qian Wang, professor in biomedical sciences at Texas A&M College of Dentistry in Dallas, identified what he and other researchers believe is likely one of the first examples of an
Oral surgery 07 October 2026
This peer-reviewed oral surgery article summarizes clinical evidence from International journal of oral and maxillofacial surgery (2026). It focuses on findings that may help dental professionals...